Topiroxostat CAS NO.577778-58-6

Boiling point     594.7±60.0 °C(Predicted)
density     1.45±0.1 g/cm3(Predicted)
storage temp.     Store at -20°C
solubility     DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)
form     Powder
pka    7.47±0.10(Predicted)
InChI    InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChIKey    UBVZQGOVTLIHLH-UHFFFAOYSA-N
SMILES    C1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1Boiling point     594.7±60.0 °C(Predicted)
density     1.45±0.1 g/cm3(Predicted)
storage temp.     Store at -20°C
solubility     DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)
form     Powder
pka    7.47±0.10(Predicted)
InChI    InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChIKey    UBVZQGOVTLIHLH-UHFFFAOYSA-N
SMILES    C1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1

Description    Topiroxostat is an orally-administered, non-purine, selective xanthine oxidase (XO) inhibitor developed for the treatment of hyperuricemia specifically for patients with gout in Japan. The drug was discovered and developed by Fuji Yakuhin. In contrast to conventional XO inhibitors such as febuxostat, topiroxostat interacts with key amino acid residues of the solvent channel.
Chemical Properties    Topiroxostat is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of topiroxostat in these solvents is approximately 10 and 20 mg/ml, respectively.
Uses    Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.
Biological Activity    Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate. Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia. In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis. Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 μM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.